{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:09:45Z","timestamp":1792098585260,"version":"4.4.0"},"reference-count":27,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,3]]},"DOI":"10.1097\/hjh.0b013e32835d6d49","type":"journal-article","created":{"date-parts":[[2013,1,10]],"date-time":"2013-01-10T17:34:30Z","timestamp":1357839270000},"page":"624-629","source":"Crossref","is-referenced-by-count":35,"title":["Sequential comparison of aldosterone synthase inhibition and mineralocorticoid blockade in patients with primary aldosteronism"],"prefix":"10.1097","volume":"31","author":[{"given":"Laurence","family":"Amar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Azizi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00ebl","family":"Menard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9verine","family":"Peyrard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre-Fran\u00e7ois","family":"Plouin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-27-20210208","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1210\/er.2007-0030","article-title":"A lifetime of aldosterone excess: long-term consequences of altered regulation of aldosterone production for cardiovascular function.","volume":"29","author":"Connell","year":"2008","journal-title":"Endocr Rev"},{"key":"R2-27-20210208","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/01.mnh.0000165889.60254.98","article-title":"Aldosterone and end-organ damage.","volume":"14","author":"Brown","year":"2005","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"R3-27-20210208","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.mce.2008.10.029","article-title":"Aldosterone and mineralocorticoid receptors: clinical studies and basic biology.","volume":"301","author":"Funder","year":"2009","journal-title":"Mol Cell Endocrinol"},{"key":"R4-27-20210208","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1210\/jcem-69-4-896","article-title":"The new aromatase inhibitor CGS-16949A suppresses aldosterone and cortisol production by human adrenal cells in vitro.","volume":"69","author":"Lamberts","year":"1989","journal-title":"J Clin Endocrinol Metab"},{"key":"R5-27-20210208","first-page":"571","article-title":"The effects of fadrozole hydrochloride on aldosterone secretion in healthy male subjects.","volume":"74","author":"Trunet","year":"1992","journal-title":"J Clin Endocrinol Metab"},{"key":"R6-27-20210208","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: a proof-of-concept study in patients with primary aldosteronism.","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"R7-27-20210208","doi-asserted-by":"crossref","first-page":"A61E583","DOI":"10.1016\/S0735-1097(10)60584-0","article-title":"Hormonal and electrolyte responses to the aldosterone synthase inhibitor lci699 in sodium depleted healthy subjects.","volume":"55","author":"Menard","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"R8-27-20210208","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1097\/00004872-198308000-00014","article-title":"Relation of blood pressure with body and plasma electrolytes in Conns syndrome.","volume":"1","author":"Beretta-Piccoli","year":"1983","journal-title":"J Hypertens"},{"key":"R9-27-20210208","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/00004872-198404000-00008","article-title":"Body elemental composition, with particular reference to total and exchangeable sodium and potassium and total chlorine, in untreated and treated primary hyperaldosteronism.","volume":"2","author":"Williams","year":"1984","journal-title":"J Hypertens"},{"key":"R10-27-20210208","first-page":"1727","article-title":"Recurrence of hypertension in primary aldosteronism after discontinuation of spironolactone. Time course of changes in cardiac output and body fluid volumes.","volume":"4","author":"Wenting","year":"1982","journal-title":"Clin Exp Hypertens A"},{"key":"R11-27-20210208","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1161\/CIRCULATIONAHA.111.029892","article-title":"Effects of a novel aldosterone synthase inhibitor for treatment of primary hypertension: results of a randomized, double-blind, placebo- and active-controlled phase 2 trial.","volume":"124","author":"Calhoun","year":"2011","journal-title":"Circulation"},{"key":"R12-27-20210208","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1097\/00004872-200103000-00001","article-title":"A review of the medical treatment of primary aldosteronism.","volume":"19","author":"Lim","year":"2001","journal-title":"J Hypertens"},{"key":"R13-27-20210208","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1097\/HJH.0b013e32832810ed","article-title":"Aldosterone-receptor antagonism in hypertension.","volume":"27","author":"Jansen","year":"2009","journal-title":"J Hypertens"},{"key":"R14-27-20210208","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1097\/HJH.0b013e3283060f0c","article-title":"Blood pressure outcome of adrenalectomy in patients with primary hyperaldosteronism with or without unilateral adenoma.","volume":"26","author":"Letavernier","year":"2008","journal-title":"J Hypertens"},{"key":"R15-27-20210208","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1056\/NEJMp030057","article-title":"Ambulatory blood-pressure monitoring in clinical practice.","volume":"348","author":"White","year":"2003","journal-title":"N Engl J Med"},{"key":"R17-27-20210208","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S0889-8529(05)70064-5","article-title":"Medical therapy for Cushings disease.","volume":"28","author":"Sonino","year":"1999","journal-title":"Endocrinol Metab Clin North Am"},{"key":"R18-27-20210208","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1093\/ndt\/gfh112","article-title":"Trends in the prevalence of primary aldosteronism, aldosterone-producing adenomas, and surgically correctable aldosterone-dependent hypertension.","volume":"19","author":"Plouin","year":"2004","journal-title":"Nephrol Dial Transplant"},{"key":"R19-27-20210208","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1097\/HJH.0b013e3283455ca5","article-title":"A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism.","volume":"29","author":"Parthasarathy","year":"2011","journal-title":"J Hypertens"},{"key":"R20-27-20210208","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.bmcl.2010.11.040","article-title":"N-(Pyridin-3-yl)benzamides as selective inhibitors of human aldosterone synthase (CYP11B2).","volume":"21","author":"Zimmer","year":"2011","journal-title":"Bioorg Med Chem Lett"},{"key":"R21-27-20210208","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule.","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"R22-27-20210208","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0140-6736(08)61236-2","article-title":"Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.","volume":"372","author":"Mann","year":"2008","journal-title":"Lancet"},{"key":"R23-27-20210208","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.cardfail.2007.11.008","article-title":"Safety and tolerability of angiotensin-converting enzyme inhibitor versus the combination of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker in patients with left ventricular dysfunction: a systematic review and meta-analysis of randomized controlled trials.","volume":"14","author":"Lakhdar","year":"2008","journal-title":"J Card Fail"},{"key":"R24-27-20210208","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1136\/bmj.e42","article-title":"The effect of combination treatment with aliskiren and blockers of the renin-angiotensin system on hyperkalaemia and acute kidney injury: systematic review and meta-analysis.","volume":"344","author":"Harel","year":"2012","journal-title":"BMJ"},{"key":"R25-27-20210208","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/01.hjh.0000226205.65442.f2","article-title":"Investigation of aldosterone-synthase inhibition in rats.","volume":"24","author":"Menard","year":"2006","journal-title":"J Hypertens"},{"key":"R26-27-20210208","doi-asserted-by":"crossref","first-page":"3072","DOI":"10.1161\/01.CIR.96.9.3072","article-title":"Synergistic effects of ACE inhibition and Ang II antagonism on blood pressure, cardiac weight and renin in spontaneously hypertensive rats.","volume":"96","author":"Menard","year":"1997","journal-title":"Circulation"},{"key":"R27-27-20210208","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1097\/00004872-200111000-00021","article-title":"Effects of combined administration of ACE inhibitor and angiotensin II receptor antagonist are prevented by a high NaCl intake.","volume":"19","author":"Griffiths","year":"2001","journal-title":"J Hypertens"},{"key":"R28-27-20210208","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/00004872-200403000-00026","article-title":"Haemodynamic effects of dual blockade of the renin-angiotensin system in spontaneously hypertensive rats: influence of salt.","volume":"22","author":"Richer-Giudicelli","year":"2004","journal-title":"J Hypertens"}],"container-title":["Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.lww.com\/00004872-201303000-00027","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T02:10:09Z","timestamp":1618366209000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004872-201303000-00027"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/hjh.0b013e32835d6d49","relation":{},"ISSN":["0263-6352"],"issn-type":[{"value":"0263-6352","type":"print"}],"subject":[],"published":{"date-parts":[[2013,3]]}}}